We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 11.00 | 12.00 | 11.50 | 11.50 | 11.50 | 5,054 | 08:00:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/3/2021 20:13 | More news anyone ? | halfpenny | |
24/3/2021 10:40 | The March contract news has impacted sentiment but the long-term growth potential remains, comments Investor's Champion. | energeticbacker | |
24/3/2021 09:48 | Yep, the bargain hunters are out .. I've put a limit buy at 48p it may never get there, but I'm not so sure I want to pay more | red ninja | |
24/3/2021 09:46 | More news ? | halfpenny | |
24/3/2021 09:43 | Can sell 30k but cannot buy 10k atm, | firw00d | |
24/3/2021 09:34 | Price still drifting downward now offer price at 56.8p. This still appears to be a falling knife. | red ninja | |
24/3/2021 00:57 | PYC seem to have clients with successful clinical trials. Especially to date Bicycle BCYC Merck MRK.DE | thiopia | |
23/3/2021 21:52 | IXI is a quality company but this is going to sting for a while but cancellations are part and parcel of the business when you work in trials. One aspect to keep in mind is when you see a large trial fail you will often see the industry pause new work in that area for a while. You can look at the experience of Cogstate in Australia and COG after a series of high profile AD trials and the initial Aducanumab futility results it took 18 months for that market to properly get back to business. Also these cancellations can cluster if they have other clients working on the same MOA as Huntingdon has been a big focus for IXI. | 40 fathoms | |
23/3/2021 20:03 | IXI bounce back will be a great opportunity | halfpenny | |
23/3/2021 17:10 | Try ITX for research purposes. Imho | jpuff | |
23/3/2021 16:37 | I got luckyish too having sold a third in the last couple of days on the immaterial cloud news. Remainder out at 86.5 and 79.95, of which the former I was pretty happy with given it had traded there recently. Can't complain at the profits overall even if a fair chunk given back right at the end. | hpcg | |
23/3/2021 16:25 | I got lucky, as I only had a handful left as I had decided to sell into strength - a previous poster having flagged the high dependency on the one customer which I wasn't aware of - and that MS collaboration RNS provided (which, by the way, I thought was pretty immaterial) the strength. Not sure you could have avoided it unless you had specific industry (company?) knowledge, and if we only invest in stuff we have detailed knowledge of, then there ain't much time for anything else. No recommendations I'm afraid, I tend to stick to stable strong balance sheet dividend payers, and dabble a bit in everything else. Recent additions include SCS (modest position) and Norcross (looks more interesting, hoping to add on any weakness) to capture excess funds in UK household (and SA in the case of Norcross) bank accounts which have nothing else to be spent on. Not much IP there! | frazboy | |
23/3/2021 15:58 | Thanks Frazboy. Yes, the customer concentration was flagged, and was a reason why I thankfully hadn't added further my position. I'll watch from the sidelines now and see where the price and next set of results settle down. Always useful in these situations to think through whether I should have been able to see this coming. Will do that over the coming days. Its also worth remembering not to beat yourself up too much either. Investing in a probabilistic game - some you win, some you lose, and you cant know the future in advance. You just need to get more right than wrong, and you WILL get some wrong. On to the next one - any suggestions for IP-rich, high ROCE small/mid caps?!? | adamb1978 | |
23/3/2021 15:52 | IXI still has great prospect with MSoft deal. Now they can focus on new development. The main contract will still partly continue as IXI products are still essential. Opportunity to top up and make a handsome gain from the current bottom. Keep on as it now means they will not be locked onto a main customer. Future looking bright. Great Product, Price and Position in this multi billion pound market with great potential. | halfpenny | |
23/3/2021 15:51 | Good back of the envelope analysis Adam. But they were meant to be expansionary, so I would think that the historic market cap/sales ratio is perhaps optimistic? Although I haven't read the annual report in detail, I hope that very large customer risk and the ability of the customer to terminate it at short notice was flagged. Best of luck all holders. | frazboy | |
23/3/2021 15:45 | Its difficult to tell where this will end up, but my guess is £7m - £8m revenues next year, given I previously had it as £12m - £13m. They also mention a £12m order book, and historically their closing order book has historically averaged 2x the next years' revenues (though there is quite a bit of variation). So £12m/2 = £6m plus some new wins gets to the same £7m - £8m area. They've historically traded around 3x revenues, which would probably now be the cap given the smell factor from this, so based on my revenue expectations, £21m - £24m mkt cap plus £8m cash gets you to £29m - £32m mkt cap, which is 62p - 67p per share. I'd say that it the cap given the sentiment around this now, and woldnt surprise me to see 50p say Quite annoying - just glad my position wasnt huge and that I was in front of my computer when the RNS came out. | adamb1978 | |
23/3/2021 15:38 | I wonder whether management had an inkling that this might be coming. They'd previously seemed keen in contract announcements to not allow expectations to get ahead of the game | adamb1978 | |
23/3/2021 15:32 | Ouch. Out. Act first, think later when profits warnings (or quasi profit warnigns) happen | adamb1978 | |
23/3/2021 15:24 | 2022 revenue was forecast at £11.2m, so £5m loss is 44.6% of this, hence almost 50%. Not quite sure why you are saying 'just', it's pretty disastrous although no doubt the bottom fishers will try to buy the drop. Commiserations to holders. | 74tom | |
23/3/2021 15:21 | I was lucky to spot the rns but couldn't get a quote for my entire holding. Managed 15k at 91p which looks good now. | alter ego | |
23/3/2021 15:20 | ... and exactly the opposite of kudos (whatever that is) to whoever bought them! | frazboy | |
23/3/2021 15:19 | How do you work our 50%?Just £2.7m and £5m on FY22 | dailylarma | |
23/3/2021 15:16 | Ouch... almost 50% of 2022 revenue down the pan. Kudos to whoever managed to sell 11000 at 1.06 about a minute after the RNS dropped! | 74tom | |
23/3/2021 15:15 | BOOOOOOOOM | jimbo123elf | |
23/3/2021 15:13 | that RNS is not good news. I thank the poster(s) who highlighted the high dependency on one customer. | frazboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions